US mRNA company Moderna (Nasdaq: MRNA) was trading more than 10% higher before markets opened on Wednesday.
This followed the announcement late Tuesday that the US government has secured 100 million doses of mRNA-1273, the company's coronavirus vaccine candidate, as part of its goal of securing early access to safe and effective COVID-19 vaccines for the American people.
The government’s award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of mRNA-1273 including incentive payments for timely delivery of the product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze